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Therapeutic Failure or Resistance to Aspirin
Gum et al. (1) recently published a highly cited study about the
potential clinical consequences of aspirin resistance as assessed by
aggregometry in patients undergoing elective cardiac catheterization.
In a recent reply to comments raised by Steinhubl et al. (2),
Topol and colleagues (3) acknowledge the real possibility of a type
II error to detect an association between long-term outcomes and
aspirin-resistance status as determined by the Platelet Function
Analyzer (PFA-100). In fact, this is a little surprising, because
previous studies indicated that PFA-100 results are highly predic-
tive of clinical outcome in stroke patients receiving aspirin (4) and
in patients with percutaneous interventions of peripheral arteries
who received clopidogrel (5). It is interesting to note that, based on
the percentages of aspirin-sensitive and aspirin-resistant-patients
presented in Gum et al. (1), Gum et al. (6), and Topol et al. (3),
the total number of patients experiencing adverse events is 35 and
43 for aggregometry and PFA-100, respectively. This inconsis-
tency needs further clarification.
What should make the reader more concerned is the high
likelihood for an alpha error regarding the main outcome of Gum
et al. (1) concerning aggregometry: the total number of aspirin-
resistant subjects is limited (n  17 of 326), of whom only four
(24%) experienced an adverse outcome, as compared to 10% of
aspirin-responsive patients. Therefore, statistical significance (p 
0.03) relies on only four events in aspirin-resistant patients, and
even one event less in this group would be likely to yield an
insignificant p value. Considering that the investigators used two
methods to assess aspirin resistance (6), the PFA-100 and the
aggregometry, a p value correction, if done for the two end points,
would also result in an insignificant p value. Thus, statistical
significance is not very robust.
The late occurrence of events is conspicuous because it contrasts
with what has been observed for the clinical efficacy of aspirin
versus placebo, where mortality curves cross after 18 to 24 months
(7). This further increases the chances for an alpha error.
Finally, Topol et al. (3) discuss the poor correlation between
aggregometry and PFA-100. This is not surprising when differ-
ences between methods are considered. The PFA-100 fulfills
several of the characteristics of an ideal and rather physiological
platelet-function test (8,9). First, whole blood is used rather than
platelet-rich plasma. Second, it is a high shear system. This is
important, because the cyclo-oxygenase inhibitor aspirin and the
purinergic receptor inhibitor clopidogrel are primarily used for
arterial indications, which are characterized by high shear rates.
In summary, several trials (1,4,5,10) have generated interest in
investigating the clinical consequences of aspirin and clopidogrel
non-responsiveness, which, it is hoped, will result in adequately
powered confirmatory studies with pivotal results.
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REPLY
In response to the letter by Dr. Jilma, I believe we have fully
addressed his concerns in our primary report (1) and the subse-
quent correspondence (2). The conclusion of our study was that
“further investigation to confirm our findings . . . should be per-
formed.” We fully acknowledged the relatively small sample size,
number of events, and potential for alpha error (1). We also duly
noted the poor correlation of the Platelet Function Analyzer
(PFA) results despite Dr. Jilma’s expectations.
Rather than investigator “resistance,” we invite Dr. Jilma to
perform meaningful prospective research to define further the
natural history of anti-platelet drug lack of responsiveness.
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Angiotensin-Converting Enzyme
Inhibitors, Beta-Blockers, and
Mortality in Systolic Heart Failure
We read with interest the study by Johnson et al. (1). We believe that
one of the key findings of this study was the relatively low rates of
angiotensin-converting enzyme inhibitor (ACEI) angiotensin recep-
tor blocker (ARB) and beta-blocker (BB) use in heart failure (HF)
patients discharged from the hospital within three months, at 44.3%
and 20.9%, respectively, from 1999 to 2000. Furthermore, only 11.3%
of these patients received both an ACEI/ARB and a BB. The
inclusion in this study of HF patients with preserved left ventricular
systolic function (LVSF), or diastolic HF, may partially account for
the low rates of utilization of these medications. The current Amer-
ican College of Cardiology/American Heart Association (ACC/
AHA) HF guidelines do not have a recommendation to use either
ACEI/ARB or BB in patients with diastolic HF. Lack of appropriate
use of ACEI/ARB and BB in HF patients with impaired LVSF or
systolic HF indicates poor quality of care and is clearly associated with
poor outcomes. Although there is pathophysiological rationale for use
of ACEI/ARB and BB in patients with diastolic HF (2), lack of use
of these drugs in diastolic HF is neither poor quality of care nor is it
associated with poor outcomes. We believe that HF quality improve-
ment programs should focus on increasing the use of ACEI and BB
in patients with systolic HF, and studies of quality and outcomes of
HF care should classify patients based on their LVSF. Furthermore,
ARBs are not currently recommended in systolic HF unless patients
have an absolute contraindication to ACEI (2). The U.S. Centers for
Medicare and Medicaid Services in its Seventh Scope of Work (2002
to 2005) identified use of ACEI, not ARB, as a quality indicator for
HF care for Medicare beneficiaries (3).
We also note with interest an apparent lack of survival benefit of
combined use of ACEI/ARB and BB on one-year mortality as
compared to therapy with ACEI/ARB alone (1). Most large random-
ized controlled trials of BBs in systolic HF enrolled patients who were
already receiving an ACEI. These studies showed that use of a BB
resulted in an additional 35% reduction in mortality in subjects
receiving both drugs compared with those receiving an ACEI alone
(4). The rate of BB use in patients with systolic HF is low (5), and we
are concerned that the finding of lack of survival benefit of BBs in HF
as shown in the study by Johnson et al. (1) might be perceived by some
clinicians as evidence that results of clinical trials do not necessarily
translate into real-life patients.
Phillip L. Thornton, RPh, PhD, CGP, FASCP
Ali Ahmed, MD, MPH, FACP, FACC
Department of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Division of Geriatric Medicine and Geriatric Heart Failure Clinic
University of Alabama at Birmingham
2000 6th Avenue South
Birmingham, AL 35233-0271
E-mail: thornph@auburn.edu
doi:10.1016/j.jacc.2004.01.005
REFERENCES
1. Johnson D, Jin Y, Quan H, Cujec B. Beta-blockers and angiotensin-
converting enzyme inhibitors/receptor blockers prescriptions after hos-
pital discharge for heart failure are associated with decreased mortality
in Alberta, Canada. J Am Coll Cardiol 2003;42:1438–45.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the
evaluation and management of chronic heart failure in the adult:
executive summary. A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Com-
mittee to revise the 1995 Guidelines for the Evaluation and Manage-
ment of Heart Failure). J Am Coll Cardiol 2001;38:2101–13.
3. IPRO. Medicare National Health Care Quality Improvement Projects.
Available at: http://www.ipro.org/index/pro_hcqip. Accessed on No-
vember 5, 2003.
4. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart
failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550–60.
5. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in
patients with chronic heart failure and reduced left-ventricular systolic
function taking angiotensin-converting-enzyme inhibitors: the CHARM-
Added trial. Lancet 2003;362:767–71.
REPLY
Drs. Thornton and Ahmed have identified one important message
from our population cohort study (1). We agree that beta-blockers
and angiotensin-converting enzyme (ACE) inhibitors/receptor
blockers were underutilized in heart failure (HF) patients in
Alberta, Canada (1), and elsewhere (2–5). We found that adjusted
one-year mortality was lower in seniors hospitalized for HF who
were prescribed beta-blockers (18.2%; 95% confidence interval
[CI] 14.2 to 22.2) or ACE inhibitor/receptor blockers (22.3%;
95% CI 20.9 to 23.7) within three months of hospital discharge
than in those with no prescriptions (29.9%; 95% CI 28.8 to 31.0).
The use of both beta-blockers and ACE inhibitors/receptor
blockers was associated with an even lower mortality (16.6%; 95%
CI 13.3 to 20.0) than ACE inhibitor/receptor blockers alone
(22.3%; 95% CI 20.9 to 23.7).
The underutilization of effective therapy is not unique (6) even
for therapies such as these that have been repeatedly documented
to be beneficial in clinical trials that span over a decade (7). To
improve the utilization of beta-blockers and ACE inhibitors/
receptor blockers, their utilization has been flagged as a marker of
quality of care. Our study may provide some clues as to why
underutilization persists. Heart failure is not defined in terms of
preservation or loss of systolic function; rather, it is a clinical
constellation of symptoms (8). Both systolic and diastolic impair-
ment in HF are independently associated with increased mortality
risk (9). Clinical trials are not representative of the general
population with HF, as younger, male, white, and decreased
ejection-fraction patients are over-represented (10). The use of the
exclusion criteria of decreased ejection fraction has the effect of
under-recruitment of older female patients. In Alberta, seniors
(age 65 years and older) constituted about 85% of all new diagnoses
for HF during the study period (April 1, 1994, to March 31,
1999). Hospitalized patients age 75 years and older constituted
about 60% of all incident, prevalent, and total hospitalization cases
during this study period. In those age 75 years and older, women
constituted over 56% of hospitalized HF patients. The population
in Alberta was similar to that noted in the United States (10).
Thus, the reflective clinician may quite rightly question whether
clinical trial results are generalizable to the demographically
different population of hospitalized HF patients. Our study can
only associate decreased mortality to the use of beta-blockers and
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